심장 바이오마커 시장 보고서 : 유형별, 검사 장소별, 용도별, 지역별(2025-2033년)

The global cardiac biomarkers market size reached USD 11.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.

Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.

Global Cardiac Biomarkers Market Drivers:

Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.

Key Market Segmentation:

Breakup by Type:

• Troponins (T and I)
• Myocardial Muscle Creatine Kinase (CK-MB)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.

Breakup by Location of Testing:

• Laboratory Testing
• Point of Care Testing

Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.

Breakup by Application:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.

Regional Insights:

• North America
• Asia Pacific
• Europe
• Middle East and Africa
• Latin America
• Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.

Competitive Landscape:

• The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.

Key Questions Answered in This Report

• 1.What was the size of the global cardiac biomarkers market in 2024?
• 2.What is the expected growth rate of the global cardiac biomarkers market during 2025-2033?
• 3.What are the key factors driving the global cardiac biomarkers market?
• 4.What has been the impact of COVID-19 on the global cardiac biomarkers market?
• 5.What is the breakup of the global cardiac biomarkers market based on the location of testing?
• 6.What is the breakup of the global cardiac biomarkers market based on the application?
• 7.What are the key regions in the global cardiac biomarkers market?
• 8.Who are the key companies/players in the global cardiac biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cardiac Biomarkers Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Type
• 5.5 Market Breakup by Location of Testing
• 5.6 Market Breakup by Application
• 5.7 Market Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Type

• 6.1 Troponins (T and I)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Myocardial Muscle Creatine Kinase (CK-MB)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Myoglobin
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Ischemia Modified Albumin (IMA)
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Location of Testing

• 7.1 Laboratory Testing
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Point of Care Testing
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Myocardial Infarction
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Congestive Heart Failure
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Acute Coronary Syndrome
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Atherosclerosis
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Middle East and Africa
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Latin America
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Global Cardiac Biomarkers Industry: SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Global Cardiac Biomarkers Industry: Value Chain Analysis

12 Global Cardiac Biomarkers Industry: Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Global Cardiac Biomarkers Industry: Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
  • 14.3.2 Alere Inc.
  • 14.3.3 Beckman Coulter
  • 14.3.4 Becton, Dickinson And Co.
  • 14.3.5 Biomerieux
  • 14.3.6 Bio-Rad Laboratories
  • 14.3.7 Randox Laboratories
  • 14.3.8 Roche Diagnostics Corporation
  • 14.3.9 Siemens Healthcare
  • 14.3.10 Thermo Fisher Scientific